All News
Filter News
Found 699 articles
-
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
5/5/2020
Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019)
-
Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update
5/4/2020
Protagonist Therapeutics, Inc. will announce first quarter financial results after the NASDAQ market closes on Thursday, May 7, 2020.
-
Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections
4/28/2020
Secarna Pharmaceuticals Gmharmaceutical c today announced that the Company has entered into a cooperation with the First Affiliated Hospital at Guangzhou Sun Yat-sen University
-
Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Disease
4/22/2020
Incyte (Nasdaq:INCY) today announced that data from the Phase 3 REACH2 study have been published in The New England Journal of Medicine demonstrating that ruxolitinib (Jakafi®) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy (BAT).
-
Imago BioSciences Appoints Bob Baltera to Board of Directors
4/22/2020
Imago BioSciences, Inc . (“Imago”), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that its Board of Directors has appointed a new independent director, Mr. Bob Baltera, Chief Executive Officer of Cirius Therapeutics. “Bob is a seasoned biotech executive who brings significant corporate development, business strategy and operational expertise to our
-
Incyte Announces Initiation of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
4/17/2020
Expanded Access Program allowing additional eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib is also open for enrollment in the United States
-
Imago BioSciences Appoints Edgardo Baracchini as Chief Business Officer
4/16/2020
Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced the appointment of Edgardo Baracchini, Ph.D., as chief business officer. Dr. Baracchini will lead the company’s corporate growth strategy, business development and partnership opportunities. “Ed is an accomplished biotechnology executive who has demonstrated his capabi
-
Protagonist Therapeutics Reports Granting of Inducement Award - April 15, 2020
4/16/2020
Protagonist Therapeutics, Inc. reported that on April 15, 2020, it issued an inducement award to Tracy Woody, the Company's recently hired Executive Vice President of Corporate Strategy, in accordance with the terms of Ms. Woody's employment offer letter.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
4/2/2020
Incyte (Nasdaq:INCY) today announced the Company is working with the U.S. Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial (RUXCOVID) to evaluate the efficacy and safety of ruxolitinib (Jakafi®) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm.
-
Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals’ LNA-modified ASOs to effectively block important immunosuppressive pathway
3/26/2020
Secarna’s approach efficiently targets IDO1 and TDO2, key enzymes that degrade the essential amino acid tryptophan into immunosuppressive kynurenine
-
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
3/10/2020
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its clinical development programs.
-
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
3/2/2020
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and year end 2019 financial results after the NASDAQ market closes on Tuesday, March 10, 2020 .
-
Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
3/2/2020
Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate immunity.
-
Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York
2/19/2020
NEWARK, Calif. , Feb. 19, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York . Presentation details: Event: SVB Leerink 9th Annual Global Healthcare Confere
-
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
2/13/2020
Incyte (Nasdaq:INCY) today reports 2019 fourth quarter and year-end financial results, announces 2020 guidance and provides a status update on the Company’s development portfolio.
-
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)
2/7/2020
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will present preclinical data on PN-943, the Company's oral, gut-restricted, alpha-4-beta-7 inhibitor candidate therapeutic, at the 15th Congress of the European Crohn's and Colitis Organization (ECCO), which will take place Feb. 12-15, 2020 , in Vienna
-
Imago Receives Fast Track Designation from U.S. FDA for Bomedemstat for Treatment of Essential Thrombocythemia
1/13/2020
Imago BioSciences, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of bomedemstat for the treatment of essential thrombocythemia, a bone marrow disease associated with high platelet counts and potentially catastrophic vascular complications.
-
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
1/7/2020
An oral, gut-restricted IL-23 receptor antagonist peptide is successfully nominated as a second-generation development candidate, advancing the collaboration and triggering a $5M milestone payment
-
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
1/6/2020
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated